The U.S. Court of Appeals for the Eighth Circuit Monday upheld a lower court ruling that dismissed a lawsuit claiming that Amgen Inc.'s Enbrel (etanercept) caused myelodysplastic syndrome (MDS) and that imposed sanctions against the plaintiff's counsel for becoming unnecessarily argumentative and filing multiple motions that the lower court described as "barely veiled attempts to re-litigate decided issues."